Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 23, 2024The Korean Journal of Internal MedicineOpen Access

A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJie LiuSLShuang LiFYFan Yang

Discussion

Loading...

Member takes

Overview

Retrospective study demonstrates roxadustat elevates hemoglobin in peritoneal dialysis patients with erythropoietin hyporesponsiveness, suggesting benefits despite existing inflammation.

Key Points

  • Roxadustat effectively increases hemoglobin levels in peritoneal dialysis patients exhibiting erythropoietin hyporesponsiveness, outperforming standard agents.
  • Mean hemoglobin increased to 118 g/L from 89.8 g/L with roxadustat, whereas erythropoiesis-stimulating agents failed to produce significant improvement.
  • Retrospective study evaluation confirms roxadustat overcomes renal anemia, indicating efficacy is unaffected by baseline intact parathyroid hormone.

Cite This Study

Liu et al. (2024) studied this question.

synapsesocial.com/papers/68e6df9ab6db64358765b37ahttps://doi.org/10.3904/kjim.2023.520
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Roxadustat for Erythropoiesis-Stimulating Agent Hyporesponsive Anemia in Hemodialysis: Multicenter Retrospective Analysis2026 · 1 citations
  2. 2P41 | Efficacy and safety of Roxadustat in patients with anemia of dialysis-dependent chronic kidney disease with or without inflammation: pooled analysis of four phase 3 studies2025
  3. 3Roxadustat for CKD-related anemia in patients undergoing peritoneal dialysis: a systematic review and meta-analysis2026
  4. 4Roxadustat in Kidney Transplant Recipients with ESA-Hyporesponsive Anemia: A Prospective Single-Center Cohort Study2026
  5. 5#2352 Short-term effect of roxadustat combined with ESA treatment for anemia in patients undergoing hemodialysis with ESA hyporesponsiveness2024